Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate

Fineline Cube Feb 10, 2026
Company Deals

GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing

Fineline Cube Feb 10, 2026
Company Deals

Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million

Fineline Cube Feb 10, 2026
Company Deals

Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market

Fineline Cube Feb 10, 2026
Company Deals

Nanjing Hanxin Licenses AC02 ACTH Analogue to Amphastar for $151 Million US/Canada Deal

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Deals Drug

Huadong Medicine and Shian Biotech Advance siRNA Obesity Therapy to Preclinical Stage

Fineline Cube Feb 10, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Shanghai Benemae’s Benaglutide Approved by NMPA for Adult Weight Management in China

Fineline Cube Jul 31, 2023

The National Medical Products Administration (NMPA) has indicated on its website that benaglutide, developed by...

Company Drug

Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA

Fineline Cube Jul 31, 2023

Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...

Company Deals

Sanofi to Boost CHC Unit with Full Acquisition of US Health Brand Qunol

Fineline Cube Jul 31, 2023

France-based pharmaceutical giant Sanofi (NASDAQ: SNY) has revealed that it has signed an agreement to...

Company Deals

AstraZeneca’s Alexion Secures Gene Therapy Portfolio in Deal with Pfizer

Fineline Cube Jul 31, 2023

AstraZeneca’s rare disease unit, Alexion (AZ, NASDAQ: AZN), has signed a significant purchase and license...

Company

AstraZeneca’s H1 2023 Financials Show 4% YOY Revenue Growth, Oncology and R&I Drive Sales

Fineline Cube Jul 31, 2023

UK-based pharmaceutical giant AstraZeneca plc (AZ, NASDAQ: AZN) has announced its financial results for the...

Company

Sanofi Reports 3.3% YOY Sales Growth in Q2 2023, Driven by Vaccines and Dupixent

Fineline Cube Jul 31, 2023

France-based Sanofi (NASDAQ: SNY) has released its financial results for the second quarter of 2023,...

Company Drug

Huadong Medicine Receives NMPA Approval for Phase I Clinical Trial of DR10624 for Weight Management

Fineline Cube Jul 31, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received approval from...

Policy / Regulatory

NMPA Seeks Public Input on Strengthening Supervision of Medical Device Contract Manufacturing

Fineline Cube Jul 31, 2023

The National Medical Products Administration (NMPA) is currently seeking public feedback on the “Opinions on...

Policy / Regulatory

China’s NHC Launches Trial Specifications for Clinical Decision Support Systems in Hospitals

Fineline Cube Jul 31, 2023

The National Health Commission (NHC) has issued a set of specifications for the application and...

Company Drug

Yingli Pharma’s YL-17231 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Jul 31, 2023

US-based Yingli Pharma, a company dedicated to developing drugs for both the China and US...

Policy / Regulatory

NHSA Issues 2023 Guidelines: Enhancing Basic Medical Insurance and Major Illness Coverage

Fineline Cube Jul 31, 2023

The National Healthcare Security Administration (NHSA) has released the “Notice on Ensuring Basic Healthcare Security...

Company Drug

Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy

Fineline Cube Jul 28, 2023

China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...

Company Deals

ACROBiosystems Partners with OBiO Technology to Advance Cell and Gene Therapy

Fineline Cube Jul 28, 2023

ACROBiosystems Group (SHE: 301080) has announced a partnership with China-based gene therapy specialist OBiO Technology...

Company Deals

Lucence and Innovent Biologics Partner to Enhance Access to Cholangiocarcinoma Treatment in Hong Kong

Fineline Cube Jul 28, 2023

Singapore-based precision medicine specialist Lucence, with a presence in Suzhou, Hong Kong, and Palo Alto...

Company Medical Device

Beijing Balance Medical’s Transcatheter Valve System Enters China’s Innovative Device Review

Fineline Cube Jul 28, 2023

China’s Beijing Balance Medical Technology Co., Ltd (SHA: 688198) has announced that its transcatheter valve...

Company Drug

Eli Lilly’s Tirzepatide Demonstrates Up to 26.6% Weight Loss in Phase III Obesity Studies

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly & Co., (NYSE: LLY) has released final results from two...

Policy / Regulatory

CDE Issues Guiding Principles for Natural History Research in Rare Disease Drug Development

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released the “Guiding Principles for Natural History Research...

Company Drug

Sino Biopharmaceutical Receives NMPA Approval for Biosimilar Herceptin for HER2+ Cancers

Fineline Cube Jul 28, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received market approval from the...

Policy / Regulatory

CDE Launches Technical Guidelines to Emphasize Patient-Centered Drug Clinical Trials

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines that encompass...

Company Drug

Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...

Posts pagination

1 … 452 453 454 … 622

Recent updates

  • Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent
  • Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate
  • GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing
  • Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million
  • Formosa Pharmaceuticals Licenses APP13007 Eye Drops to Samil Pharma for South Korea Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Digital

Xianju Pharmaceutical and Adamerck Grant Aspen China Rights to Aomeikesong Neuromuscular Reversal Agent

Company Deals

Zhendong Pharmaceutical Secures China Promotion Rights to Ferring’s Sodium Picosulfate

Company Deals

GenAssist Therapeutic Partners with Indian DART Foundation on Duchenne Muscular Dystrophy Base Editing

Company Deals

Foresee Pharmaceuticals Licenses MMP-12 Inhibitor Portfolio to Primevera for $584.5 Million

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.